Improved Method for Obtaining Patient‐Derived Glioblastoma Organoid and Primary Cells: A Generic and Simplified Approach for Intracranial Tumor With Minimized Input

INTRODUCTION: Glioblastoma is one of the most malignant primary tumors in adults. The shortages of the traditional tumor models obstruct the development of basic research and therapeutic modes. Application of organoid is critical to keep tumoral heterogeneity and microenvironment. The current method for generating glioblastoma organoid is sophisticated, laborious, and inconvenient. METHODS: We collected glioblastoma tissue samples from patients and used an improved methodology to generate organoids. Subsequently, the collected suspension during the process was used to isolate primary tumor cells. Organoid were used to assess its drug susceptibility. Finally, we generated organoids of other CNS tumors with the same method. RESULTS: The improved method took less time and lowered technical requirements. Glioblastoma organoids generated with our improved method can be cultured for further research. Primary glioblastoma cells isolated from collected medium were proved with immunofluorescence. Patient-derived glioblastoma organoids showed consistent drug susceptibility with the patients. Tumor organoids were also generated successfully from patient's lymphoma and low-grade glioma samples. CONCLUSIONS: We improved an easier and rapider method to generate glioma organoids from tissue samples and avoided wasting primary tumor cells in used medium. This method established a technical foundation for the widely application of organoids in neuro-oncology tumor research and clinical decision-making.